Biotech, Up 181%, Faces Its 'Worst-Case Scenario' And Dives
Biotech, Up 181%, Faces Its 'Worst-Case Scenario' And Dives
4 months ago
investors.com
Latest read on first-in-disease therapy from Insmed CEO Will Lewis
5:01
Latest read on first-in-disease therapy from Insmed CEO Will Lewis
5 months ago
MSNCNBC
Insmed CEO on its Arikayce drug after shares surge on trial results
5:19
Insmed CEO on its Arikayce drug after shares surge on trial results
3 weeks ago
MSNCNBC
Insmed Says Brensocatib Showed Consistent Efficacy in Non-Cystic Fibrosis Bronchiectasis
Insmed Says Brensocatib Showed Consistent Efficacy in Non-Cystic Fibrosis Bronchiectasis
11 months ago
marketscreener.com
Insmed Says Brensocatib Showed Consistent Efficacy in Non-Cystic Fibrosis Bronchiectasis
Insmed Says Brensocatib Showed Consistent Efficacy in Non-Cystic Fibrosis Bronchiectasis
11 months ago
marketscreener.com
Transcript : Insmed Incorporated, Q1 2025 Earnings Call, May 08, 2025
Transcript : Insmed Incorporated, Q1 2025 Earnings Call, May 08, 2025
11 months ago
zonebourse.com
Insmed Incorporated | LinkedIn
Insmed Incorporated | LinkedIn
9 months ago
linkedin.com
Insmed Incorporated présente de nouvelles analyses de sous-groupes de l'étude ASPEN de phase 3 sur le brensocatib chez les patients atteints de bronchiectasie, qui démontrent la cohérence avec les résultats positifs de l'ensemble de la population étudiée
Oct 8, 2024
zonebourse.com
Insmed TV Spot, 'Loud'
6 months ago
iSpot.tv
Insmed Incorporated: FDA Approves BRINSUPRI (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
8 months ago
finanznachrichten.de
Insmed (INSM) Q4 2025 Earnings Call Transcript
1 month ago
aol.co.uk
5:21
Insmed CEO Will Lewis talks its rare disease drug pipeline
3 months ago
CNBC
European Commission Approves Insmed's Chronic Lung Disease Treatment
5 months ago
marketscreener.com
Insmed Drug for Chronic Lung Ailment Meets Main Endpoint in Trial
Feb 3, 2020
thestreet.com
3:02
Josh Brown's Best Stocks in the Market: Insmed
8 months ago
MSNCNBC
4:40
Mizuho's Jared Holz talks Insmed sinking double digits on sinus drug trial news
4 months ago
MSNCNBC
0:25
FDA approves Brinsupri (brensocatib), a small molecule DPP1 inhibitor, for adults & adolescents with non-cystic fibrosis bronchiectasis. Learn more about trial data, disease impact & commercial rollout at https://buff.ly/OjakPGX by Soumya Shashikumar. #Brinsupri #Brensocatib #Insmed #NonCysticFibrosisBronchiectasis #NCFB #FDAApproval #DPP1Inhibitor #SmallMoleculeDrug #PulmonaryDisease #RareLungDisease | Xtalks Webinars
140 views8 months ago
FacebookXtalks Webinars
5:06
Insmed CEO on what’s next for company after FDA greenlights lung disease drug
8 months ago
MSNCNBC
5:30
Insmed is nearly on pace with Palantir for gains this year - nearly tripling! What are the next catalysts for the high-flyer in the gene therapy space and beyond? CEO Will Lewis breaks it down | CNBC Fast Money
2.2K views5 months ago
FacebookCNBC Fast Money
3:31
ASPEN Trial Shows Efficacy of Brensocatib in Different Dosages: James Chalmers, MD | AJMC
10 months ago
ajmc.com
Brinsupri ™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
6 months ago
empr.com
3:09
Our sponsor Insmed is raising awareness for chronic inflammatory lung condition bronchiectasis. Spokesperson Martina Flammer and real patient Lavonda are sharing their stories. You can learn more here: exploreBE.com | Good Morning America
332.2K views5 months ago
FacebookGood Morning America
Brensocatib Leads to Lower Rate of Pulmonary Exacerbations in Bronchiectasis
191 views1 year ago
diabetesincontrol.com
5:15
Insmed CEO on lung disease treatment and path forward
May 28, 2024
CNBC
Is Insmed Incorporated (INSM) Going to Burn These Hedge Funds?
Jun 19, 2020
insidermonkey.com
3:58
Is the $INSM pullback a buying opportunity in this red-hot biotech stock? @MizuhoAmericas strategist Jared Holz unpacks the sinusitis drug trial miss and how to play the stock. | CNBC Fast Money
2.9K views4 months ago
FacebookCNBC Fast Money
Bridgewater firm's stock jumps after FDA approves its new lung disease drug
8 months ago
mycentraljersey.com
2:59
$INSM | Insmed — 3 Min Breakdown
8 views1 month ago
YouTubeYMYC AI - Your Money Your Call
41:17
02 Insmed_NTM-B - Webinar - Radiology in Bronchiectasis and NTM
10 months ago
VimeoCHEST
0:28
Barış Ve Damlalar on Instagram: "ABD Gıda ve Ilaç Bürosu FDA #brinsupri isimli ilacı #bronşektazi hastalığının ilk ve tek tedavisi olarak onayladı…Barış Hoca nın çalışmaları ve gayretleri sonunda #brinsupri isimli antienflamatuvar ilaç adayı (dipeptidyl peptidase (veya cathepsin C) inhibitoru) #bronşektazi hastalarında FAZ 3 denemelerinde etki gösterdi. B. Korkmaz Brensocatib AR-GE bilim kurulu başkanı: Klinik denemelere Türkiye de katıldı…Dosya aralık 2024 se ABD Gıda ve İlaç Bürosu FDA ya
11.4K views8 months ago
Instagrambaris.damlalar.fransa
See more